30.06.2014 Views

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

DRUGS USED TO TREAT TACHYARRHYTHMIAS<br />

A<br />

B<br />

Fast sodium<br />

channels<br />

K + Na +<br />

Na 2+ Ca 2+<br />

Cardiac cell<br />

Outward potassium<br />

current<br />

Cardiac cell<br />

Slow calcium<br />

channels<br />

Slow calcium<br />

channels<br />

Slow sodium<br />

channels<br />

formation of impulses that arise from ectopic foci and<br />

have spontaneous activity or the abnormal propagation<br />

of impulses, where an extra anatomical or functional<br />

circuit exists so that the electrical impulse may take two<br />

possible pathways with different conduction velocities<br />

and refractory periods. The latter mechanism is termed<br />

re-entry.<br />

Abnormal automaticity is a common form of abnormal<br />

impulse formation in small animals. In this abnormality,<br />

partly damaged cells become partially depolarized,<br />

attaining a resting membrane potential similar to automatic<br />

cells in the heart, such as the sinus node. When<br />

this occurs these cells attain the property of automaticity.<br />

When they depolarize at a rate faster than the<br />

normal pacemaker (i.e. automatic) cells, they take over<br />

control of the heart rate, sometimes for only one beat<br />

and at other times for long periods. All forms of abnormal<br />

impulse arrhythmia tend to be exacerbated by ischemia,<br />

high catecholamine concentrations and electrolyte<br />

imbalances, particularly decreased potassium and magnesium<br />

concentrations. Other forms of abnormal<br />

impulse formation are early and delayed or late afterdepolarizations<br />

and triggered activity.<br />

Outward potassium<br />

current<br />

Fig. 17.1 Generation of action potentials in (A) normal<br />

myocardial cells and (B) normal pacemaker cells.<br />

● During electrical diastole ionic balances are restored<br />

by membrane pumps that exchange sodium for<br />

potassium and calcium for sodium.<br />

Pacemaker cells (SA and AV nodes), ischemic<br />

myocardial cells (Fig. 17.1B)<br />

● The initial part of the action potential in these cells<br />

is due to a slow inward calcium current. This results<br />

in the initial part of the action potential being very<br />

slow, thus slowing conduction through the SA and<br />

AV nodes. This results in a delay between atrial and<br />

ventricular contraction, allowing time for adequate<br />

ventricular filling.<br />

● Diastolic depolarization occurs because of a steadily<br />

declining outward potassium current and an increasing<br />

slow diastolic inward, predominantly sodium,<br />

current. The inward sodium current eventually reaches<br />

a threshold so that calcium ions start to flow in, hence<br />

initiating another action potential – automaticity.<br />

Arrhythmias<br />

Arrhythmias originate in either the atria (supraventricular<br />

arrhythmias) or the ventricles (ventricular arrhythmias).<br />

They can arise as a result of either the abnormal<br />

DRUGS USED TO TREAT<br />

TACHYARRHYTHMIAS<br />

The effective treatment of tachyarrhythmias is predicated<br />

on an accurate rhythm diagnosis and a working<br />

knowledge of the available antiarrhythmic drugs. The<br />

reader is referred elsewhere to learn rhythm diagnosis.<br />

Classes of antiarrhythmic agents<br />

The drugs used to treat supraventricular and ventricular<br />

tachyarrhythmias can be divided into separate classes<br />

based on their generalized mechanisms of action.<br />

Antiarrhythmic drugs exert their effects primarily by<br />

blocking sodium, potassium or calcium channels, or β-<br />

receptors. This classification scheme is somewhat helpful<br />

clinically when deciding to use particular drugs for specific<br />

arrhythmias. However, clinical experience with<br />

these drugs is the more important means of determining<br />

efficacy of various drugs to suppress different tachyarrhythmias.<br />

The common arrhythmias, the mechanisms<br />

responsible for their generation and the drugs most<br />

commonly effective clinically are listed in Table 17.6.<br />

The doses of the common antiarrhythmic agents are<br />

listed in Table 17.7.<br />

Class I<br />

Class I drugs are most frequently used to treat ventricular<br />

tachyarrhythmias, although they may also be used<br />

to treat supraventricular tachyarrhythmias. They are the<br />

425

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!